Opinion|Videos|December 23, 2024
Patient Education: Preparing Patients for ALK Inhibitor Treatment
Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you approach patient education regarding potential adverse events associated with lorlatinib and other ALK inhibitors? What do you tell patients to expect and about when to contact their care team?
Advertisement
Related to this article
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.
At ASTRO 2026, Dr. Nitin Ohri details additive versus synergistic toxicities when combining radiation with novel systemic therapies in clinical trials.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Navigation Boosts Cascade Genetic Testing in Relatives of BRCA Carriers
2
Multidisciplinary Support for Patients with Metastatic Triple-Negative Breast Cancer
3
Managing Oral and Ocular Toxicities in Metastatic Triple-Negative Breast Cancer
4
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
5